Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:37:55.266Z.
Calculation as of: 2026-10-06T16:37:55.266Z.
Quote observation: 2026-10-06T16:35:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 295890ca45b9fb7c845dc9b7cfc12ce3e82df22f7cd737cbd4420fef5fb5231a
PEG RATIO
N/A
Liquidia Corporation
Market Cap
$2.32B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Liquidia Corporation (LQDA) | $2.32B | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.36B | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.40B | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.43B | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.14B | N/A |
PEG Ratio
N/A
P/E Ratio
19.1
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
